Suppr超能文献

用于增强载依巴斯汀固体脂质纳米粒递送的口腔崩解膜的开发与优化

Development and Optimization of Oral Dissolution Films for Enhanced Delivery of Ebastine-Loaded Solid Lipid Nanoparticles.

作者信息

Chen Kai, Sun Yong

机构信息

Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, 266021, People's Republic of China.

Pharmacy Department, Affiliated Hospital of Jining Medical University, Jining, 272000, People's Republic of China.

出版信息

Int J Nanomedicine. 2025 May 30;20:6963-6981. doi: 10.2147/IJN.S521504. eCollection 2025.

Abstract

INTRODUCTION

Approximately 10-30% of the worldwide population suffers from allergic diseases. Although ebastine (EBT) is described as a potential treatment for allergies, its effects are compromised due to poor solubility and low bioavailability.

METHODS

This study introduced a novel delivery platform for ebastine by combining solid lipid nanoparticles (SLNs) with oral dissolution films (ODFs). Ebastine SLNs were fabricated using hot melt and ultrasonic emulsification methods, and the SLNs' formulation was optimized by a central composite rotatable design. The developed SLNs were further introduced into a mixed polymer solution of PVA and HPMC to prepare ODFs using the solvent casting method.

RESULTS

The optimized EBT-SLNs with spherical structures demonstrated nanoparticle size (147.5 ± 3.32 nm), low polydispersity index (PDI, 0.106 ± 0.005), high entrapment efficiency (86.7%), as well as drug loading (10.02%), respectively. The optimum formulation of ODFs was composed of equal proportion of HPMC and PVA according to normalization methods by evaluation of physicochemical properties including physical appearance, folding endurance and disintegration time. Scanning electron microscopy results disclosed that EBT-SLNs were confined within the network of ODFs and no aggregation SLNs was found. Reconstitution experiments showed EBT-SLNs were still within the nanometers range and maintained a homogenous state, suggesting that incorporation of SLNs into ODFs not compromised their nanoparticulate properties. The in vitro drug release patterns from ODFs containing EBT-SLNs exhibited a fast release profile compared to the commercial EBT tablets.

DISCUSSION

The developed system demonstrates enhanced solubility, stability, and bioavailability of ebastine, offering a promising alternative to traditional oral tablets, with potential advantages in patient compliance and rapid drug onset. Therefore, the ODFs containing SLNs can be considered as an efficient approach for EBT administration.

摘要

引言

全球约10%-30%的人口患有过敏性疾病。尽管依巴斯汀(EBT)被描述为一种潜在的过敏治疗药物,但其疗效因溶解度差和生物利用度低而受到影响。

方法

本研究通过将固体脂质纳米粒(SLNs)与口服溶出膜(ODFs)相结合,引入了一种新型的依巴斯汀给药平台。采用热熔法和超声乳化法制备依巴斯汀SLNs,并通过中心复合旋转设计对SLNs的配方进行优化。将制备好的SLNs进一步引入聚乙烯醇(PVA)和羟丙基甲基纤维素(HPMC)的混合聚合物溶液中,采用溶剂浇铸法制备ODFs。

结果

优化后的具有球形结构的EBT-SLNs的纳米颗粒尺寸为(147.5±3.32 nm),多分散指数(PDI)低(0.106±0.005),包封率高(86.7%),载药量为(10.02%)。通过对外观、耐折性和崩解时间等理化性质的评估,采用归一化方法确定ODFs的最佳配方为HPMC和PVA等比例组成。扫描电子显微镜结果显示,EBT-SLNs被限制在ODFs的网络结构中,未发现SLNs聚集。复溶实验表明,EBT-SLNs仍处于纳米范围内并保持均匀状态,这表明将SLNs掺入ODFs中不会损害其纳米颗粒性质。与市售EBT片剂相比,含EBT-SLNs的ODFs的体外药物释放模式呈现快速释放特征。

讨论

所开发的系统显示出依巴斯汀的溶解度、稳定性和生物利用度均有所提高,为传统口服片剂提供了一种有前景的替代方案,在患者依从性和药物快速起效方面具有潜在优势。因此,含SLNs的ODFs可被视为一种有效的依巴斯汀给药途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5302/12132053/378f6ea73a5f/IJN-20-6963-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验